RxDoctor Payments Data

Caleb Thompson, MD

Interventional Cardiology · San Luis Obispo, CANPI 1962606913

Payments from drug & device makers

$14,960in general payments, 2019–2025

Across 195 payments — averaging $76.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Edwards Lifesciences$4K
  • Abiomed$3K
  • Medtronic$1K
  • Boston Scientific$1K
  • Biosense Webster, Inc.$238
  • plus $1K from 12 others

What the payments were for

  • Grants$2001%
  • Travel & lodging$4,45030%
  • Food & beverage$10,02867%
  • Other$2822%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,960 in reported general payments places this provider in the 55th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$205,142
Medicare patients
638
Services billed
1,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$133,310
FarxigaDapagliflozin Propanediol97$94,052
EntrestoSacubitril/Valsartan86$93,651
XareltoRivaroxaban61$81,104
BrilintaTicagrelor66$50,086
JardianceEmpagliflozin19$21,989
Metoprolol Succinate141$1,950
ClopidogrelClopidogrel Bisulfate158$1,856
Rosuvastatin Calcium133$1,491
Atorvastatin Calcium119$1,274
Chlorthalidone51$979
Losartan Potassium102$949
Carvedilol81$779
Ezetimibe13$702
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$38$144,138163 claims
Johnson & JohnsonXarelto$17$81,10461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in San Luis Obispo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →